JeKo-1 Cells
USD$395.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | The JeKo-1 cell line is an established human mantle cell lymphoma (MCL) cell line derived from an adult patient. Mantle cell lymphoma is a type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1 due to the t(11;14)(q13;q32) chromosomal translocation. JeKo-1 cells exhibit this hallmark genetic aberration, making them a valuable model for studying the pathophysiology of MCL and testing therapeutic agents targeting the cyclin D1 pathway. These cells grow in suspension and possess a doubling time that facilitates robust experimental use in various high-throughput screening applications. JeKo-1 cells are particularly useful in research focused on the molecular mechanisms of MCL, including the exploration of B-cell receptor (BCR) signaling pathways, apoptosis resistance, and drug resistance mechanisms. Additionally, this cell line serves as a model for studying the interaction between tumor cells and the microenvironment, especially in the context of lymphoid malignancies. Due to its well-characterized genetic background and consistent behavior in vitro, JeKo-1 is frequently utilized in the development and testing of novel anti-cancer compounds, particularly those aimed at overcoming chemoresistance in MCL. |
|---|---|
| Organism | Human |
| Tissue | Peripheral blood |
| Disease | Mantle cell lymphoma |
| Synonyms | Jeko-1, JEKO-1, JeKo 1, Jeko1, JEKO1, JEKO |
Characteristics
| Age | 78 years |
|---|---|
| Gender | Female |
| Morphology | Lymphoblast |
| Growth properties | Suspension |
Regulatory Data
| Citation | JeKo-1 (Cytion catalog number 305078) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_1865 |
Biomolecular Data
| Protein expression | Cd3-, Cd5+, Cd10+, Cd19+ |
|---|---|
| Antigen expression | CD3-, CD5+, CD10+, CD19+ |
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 20% heat-inactivated FBS |
| Subculturing | Gently homogenize the cell suspension in the flask by pipetting up and down, then take a representative sample to determine the cell density per ml. Dilute the suspension to achieve a cell concentration of 5 x 105 cells/ml with fresh culture medium, and aliquot the adjusted suspension into new flasks for further cultivation. |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305078-180825 | Certificate of Analysis | 22. Oct. 2025 | 305078 |
| 305078-050824 | Certificate of Analysis | 23. May. 2025 | 305078 |